Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
life sciences
national blog main
boston
fda
new york blog main
alirocumab
alnylam pharmaceuticals
amgen
biotech ipos
cancer
codiak biosciences
cutaneous t-cell lymphoma
deals
dyne therapeutics
evolocumab
exosome
inclisiran
jazz pharmaceuticals
metacrine
myotonic dystrophy type 1
national top stories
new york
new york top stories
nonalcoholic steatohepatitis
novartis
pcsk9
pcsk9 inhibitors
rare disease drugs
rare diseases
regeneron pharmaceuticals
rna interference
salk institute
san diego blog main
san diego top stories
sanofi
sarepta therapeutics
What
brings
3
×
medicines
3
×
company
drug
ipo
million
new
acquire
agreed
based
begin
billion
biosciences
bio’s
bubbles
cash
cells
cholesterol
class
clinical
codiak
compound
deal
developing
disorders
dyne
dyne’s
exosome
exosomes
fda
formed
fund
genetic
medco
muscle
muscular
novartis
poised
preclinical
raised
Language
unset
3
×
Current search:
brings
×
unset
×
medicines
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B